Enhancing shareholder value through exceptional business performance and practices, and through responsible and effective communication with its shareholders.
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced new in vitro data demonstrating the therapeutic potential of HT-003 to block acne pathogenic gene expression in...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the Pre-IND meeting requested on 22 December 2020 for HT-001 with the U.S. Food and Drug Administration (FDA)...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced an agreement with Charles River Laboratories to initiate preclinical studies of HT-001, a topical formulation...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has entered into a definitive securities purchase agreement in connection with a private placement to...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has entered into a Non-Exclusive Commercial Evaluation License Agreement with the U.S. Army Medical...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has signed a production agreement for both GLP and GMP materials associated with HT-001 with Tergus...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the request for a Pre-Investigational New Drug (IND) meeting to the U.S. Food and Drug Administration (FDA) to...
Hoth (NASDAQ: HOTH) has a partnership agreement with Zylö Therapeutics Inc.,to co-develop a new topical treatment for patients with Cutaneous Lupus Erythematosus (CLE), a chronic autoimmune...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that is has received Human Research Ethics Committee (HREC) clearance to commence the first cohort of the Phase...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced positive, statistically significant proof-of-concept preclinical data on its therapeutic HT-005 for the...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced key upcoming milestones towards the commercial development of the novel COVID-19 products currently being...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that through its commercial licensing agreement with the University of Maryland, Baltimore (UMB) the U.S....
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced completing testing to examine the ability of HT-003 to block acne pathogenic gene expression in human...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has entered into a Sponsored Research Agreement ("SRA") with the George Washington University ("GW")...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced Dr. Stefanie Johns, who has agreed to join Hoth and serve as its Chief Scientific Officer, is scheduled to...
Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company, today announces the appointment of Stefanie Johns, Ph.D., to the position of Chief Scientific Officer, effective September 2020....
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Chief Executive Officer, Robb Knie, is scheduled to present at the following investor conferences in...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today is providing shareholders with a update on its COVID-19 initiatives including vaccine and real-time, breath-based mobile...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has submitted for ethics approval in Australia for its planned Clinical study of its therapeutic...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced licensing the intellectual property rights relating to the development of a medical device that has the...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has executed a licensing agreement with Isoprene Pharmaceuticals, Inc. to acquire the rights to VNLG-152, a...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced entering into a sponsored research agreement with Virginia Commonwealth University (VCU) for a potential...
Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company, today announced that it has expanded its sponsored research agreement with the George Washington University (GW) to explore the...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Scientific Advisory Board member and inventor of novel peptide COVID-19 therapeutic, Michael H. Peters,...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for US Patent...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today provided an update on its pipeline of therapeutics including six compounds in various stages of clinical development,...
Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ: HOTH), a biopharmaceutical company, announced today the closing of its previously announced underwritten public offering of 1,818,182...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Michael H. Peters, Ph.D., has joined the company's Scientific Advisory Board. Dr. Peters is the inventor...
Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ: HOTH), a biopharmaceutical company, today announced the pricing of an underwritten public offering of 1,818,182 shares of common stock at...
Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ: HOTH), a biopharmaceutical company, today announced that it intends to offer shares of its common stock in an underwritten public...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced licensing technology and intellectual property exclusively from Virginia Commonwealth University ("VCU") for a...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced today that the company has obtained exclusive worldwide licensing rights to the BioLexa Platform, a...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has completed a strategic investment in Zylö Therapeutics, Inc ("Zylö"). Mr. Robb Knie, Chief Executive...
Hoth Therapeutics, Inc. (Nasdaq: HOTH) announced today that Voltron Therapeutics, Inc has selected the peptides required to complete the structure of HaloVax for development and progression into...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced hosting a shareholder update conference call with Dr. Mark Poznansky on Thursday, April 23, 2020 at 10:15 a.m....
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced hosting a shareholder update conference call with Dr. Mark Poznansky on Thursday, April 23, 2020 at 10:15 a.m....
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced top line data from its Cutaneous Lupus Erythematosus (CLE) study, a chronic autoimmune skin disease, in...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the addition of two independent members, Mr. Graig Springer and Mr. Wayne Linsley, to its Board of Directors....
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Dr. Mark Poznansky, Co-Creator of VaxCelerate, a self-assembling vaccine (SAV) platform, appeared as a...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced initiating the next phase of its study of VNLG-152 novel retinamides (Retinoic acid metabolism blocking agents...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced its joint venture entity with Voltron Therapeutics, Inc., HaloVax, has entered into a Sponsored Research...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has entered into a non-binding letter of intent ("LOI") with Isoprene Pharmaceuticals, Inc. to acquire the...
Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("Hoth" or the "Company"), a biopharmaceutical company, today announced the pricing of its previously announced "best efforts" underwritten public offering...
Hoth Therapeutics Inc. (Nasdaq: HOTH) ("Hoth" or the "Company"), a biopharmaceutical company, today announced that it intends to offer shares of its common stock in a "best efforts" underwritten...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has reached an agreement with Voltron Therapeutics, Inc. (Voltron) to form a joint venture entity, to be...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has reached an agreement with Voltron Therapeutics, Hoth Therapeuticsto form a joint venture entity (to be...
Hoth Therapeutics, Inc. (NASDAQ: HOTH) (the "Company' or "Hoth"), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging...
Diamond Equity Research, an equity research firm with a focus on micro capitalization and small capitalization public companies has released a comprehensive update note of Hoth Therapeutics, Inc....
Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis,...
Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis,...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis,...
Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis,...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis,...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing new generation therapies for dermatological and immunological disorders such as atopic dermatitis,...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing new generation therapies for dermatological and immunological disorders such as atopic dermatitis,...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis,...
Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological and immunological disorders such as...
Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis,...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic...
Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis,...
Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis,...
Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis,...
Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis,...
Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis,...
Hoth Therapeutics, Inc. (Nasdaq:HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic...
Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as...
Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as...
Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as...
Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as...
Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as...
Hoth Therapeutics, Inc. (Nasdaq: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis to...
Hoth Therapeutics, Inc. (Nasdaq: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis to...
Hoth Therapeutics, Inc. (NASDAQ: HOTH) a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic...
Hoth Therapeutics, Inc. (Nasdaq: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as...
Hoth Therapeutics, Inc. (Nasdaq: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as...
Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as...
Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis-also known as eczema-as...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis-also known as...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as...
Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as...
Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as...
Hoth Therapeutics, Inc.(NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a development-stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a development-stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic...
Hoth Therapeutics, Inc. (NASDAQ: HOTH) a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic...
Hoth Therapeutics Inc. ("Hoth" or the "Company"), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic...
Hoth Therapeutics Inc. ("Hoth" or the "Company"), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic...
Hoth Therapeutics Inc. ("Hoth" or the "Company"), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic...
Hoth Therapeutics Inc. ("Hoth" or the "Company"), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic...
Hoth Therapeutics Inc., a Nevada corporation ("Hoth" or the "Company"), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from...
Hoth Therapeutics Inc., a Nevada corporation ("Hoth" or the "Company"), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from...
